Fosravuconazole by Eisai for Tinea Pedis (Athlete Foot): Likelihood of Approval

Fosravuconazole is under clinical development by Eisai and currently in Phase II for Tinea Pedis (Athlete Foot).

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression | Psychedelic Invest

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions today announced that the U.S.

September 18, 2023

Microplastics in the Brain; Amyloid After COVID; Alzheimer’s and Extreme Heat

Concentrations of microplastics and nanoplastics were higher in brain tissue than they were in liver or kidney tissue in post-mortem samples. (Nature Medicine) People with

February 5, 2025

PF-08046054 by Pfizer for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

February 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.